Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00029003 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

NIH

Sponsor class

Conditions

Bronchoalveolar Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: gefitinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)